Physical and Pasting Properties of ‘Ofada’ Rice (Oryza sativa L.) Varieties

ABSTRACTIn this study, grain physical and pasting properties of ofada rice cultivated in South-West Nigeria was evaluated using Standard Evaluation System (SES) for rice with the aim of providing basic information for brand development and utilization of ofada in the development of novel food products. Results showed that size and shape of ofada rice ranged from 5.9 to 9.0mm and 1.8 to 3.0mm respectively. The 1000-grain weight was between 24.0 to 31.0g. Percentage hull was significantly different among the cultivars, ranging from 16 to 21. Peak viscosity ranged between 112.7 and 152.8 BU, minimum, setback and final viscosities varied from 80.3 to 117.2 BU, 104.0 to 143.3BU and 190.8 and 232.3 BU respectively. Gelatinization temperature was not significantly different and varied between 64.1 to 64.7°C. Significant difference (p<5%) was observed among the samples in terms of minimum setback and final viscosities respectively. Significant negative association was observed between kernel length and gelatinization temperature (r=– 0.65), setback and gelatinization temperature (r=– 67) while positive correlation was observed between breakdown viscosity and peak viscosity (r=0.86). The good pasting behaviour makes ofada flour good material for the production of stiff dough products, better palatability and water binding capacity while physical qualities give ofada an advantage during milling. This attributes could be exploited for the development of new varieties and utilization in food development of the ofada rice value-chain

Effect of different pretreatments on egyptian sugar-cane bagasse saccharification and bioethanol production

AbstractSugar-cane processing generates large amount of bagasse. Disposal of bagasse is critical for both agricultural profitability and environmental protection. Sugar-cane bagasse is a renewable resource that can be used to produce ethanol.In this study, twelve microbial isolates, five bacteria, four yeasts and three filamentous fungi were isolated from sugar-cane bagasse. Bacterial and yeast isolates were selected for their ability to utilize different sugars and cellulose. Chipped and ground bagasse was subjected to different pretreatment methods; physically through steam treatment by autoclaving at 121°C and 1.5bar for 20min and/or different doses of gamma γ irradiation (50 and 70Mrad). Autoclaved pretreated bagasse was further biologically treated through the solid state fermentation process by different fungal isolates; F-66, F-94 and F-98 producing maximum total reducing sugars of 18.4., 26.1 and 20.4g/L, respectively.Separate biological hydrolysis and fermentation (SHF) process for bagasse was done by the two selected fungal isolates; Trichoderma viride F-94 and Aspergillus terreus F-98 and the two yeast isolates identified as Candida tropicalis Y-26 and Saccharomyces cerevisiae Y-39. SHF processes by F-94 and Y-26 produced 226kg of ethanol/ton bagasse while that of F-98 and Y-39 produced 185kg of ethanol/ton bagasse

Impacts of tea tree or lemongrass essential oils supplementation on growth, immunity, carcass traits, and blood biochemical parameters of broilers reared under different stocking densities

The effects of tea tree essential oil (TTEO) and lemongrass essential oil (LGEO) with different stocking densities on the growth performance, biochemical markers, antioxidants, and immunity state of broiler chickens were studied. Birds were housed at stocking densities of 25, 30, 35, and 40 kg/m2. The treatments were, basal diet without any supplementation, the second and third groups were supplemented with 300 mg TTEO/kg feed, and 300 mg LGEO/kg feed, respectively. Results revealed that increasing stocking density from 25 to 40 kg/m2 significantly reduced body weight and daily weight gain at different ages. The phagocytic index and activity were significantly higher under the lower stocking density (25 kg/m2). Serum amyloid A (SAA), serum or liver transferrin (TRF), or C-reactive protein (CRP) were significant decreased when decreasing stocking density. Increasing stocking density from 25 to 40 kg/m2 resulted in a significant increase in the serum urea, creatinine, uric acid, lactate dehydrogenase (LDH), alanine aminotransferase (ALT), aspartate aminotransferase (AST), malondialdehyde (MDA), and catalase (CAT) levels. However, there was a significant reduction in antioxidant enzyme activity, including glutathione peroxidase (GPx) and superoxide dismutase (SOD), as stocking density increased. The supplementation of TTEO produced significantly higher body weight and daily weight gain followed by LGEO. Additionally, the mortality rates were reduced in TTEO (27.4%) and LGEO (25%) groups. TTEO or LGEO supplementation significantly improved meat constituents and cellular immunity and reduced serum total lipids, serum and meat cholesterol, and triglycerides, SAA, TRF, and CRP. For all these measured parameters, superior results were obtained when TTEO was used compared to LGEO. TTEO or LGEO supplementation also significantly reduced serum urea, creatinine, uric acid, and the enzymatic activities of LDH, ALT, AST, MDA, and CAT (but not GPx and SOD) in comparison to the control treatment. Overall, our results showed the superiority of TTEO over LGEO as a feed supplement in broiler diets. In conclusion, TTEO treatment offers a better solution for raising broiler chickens in high stocking density

Family systemic psychosocial support for at-risk adolescents in Lebanon: study protocol for a multi-site randomised controlled trial

Background: Adolescents growing up in communities characterised by adversity face multiple risk factors for poor mental health and wellbeing. There is currently a scarcity of research on effective approaches for preventing and treating psychological distress in this population, particularly in humanitarian settings. The powerful impact of the home environment and family support is well known; however, approaches targeting the family are seldom developed or evaluated in such settings. We developed a brief family systemic psychosocial support intervention to be delivered through existing child protection systems with non-specialist facilitators. This paper outlines the study protocol for a randomised controlled trial of the intervention in Lebanon.Methods: We will conduct a single-blind hybrid effectiveness-implementation multi-site RCT comparing the locally developed systemic family intervention to a waitlist control group for families residing in vulnerable regions in North Lebanon and Beqaa governorates (including families of Syrian, Palestinian, and Lebanese backgrounds). Outcomes on a range of family, adolescent, and caregiver measures will be assessed at baseline (T0) and post-intervention (T1), and at a 3-month follow-up for the treatment arm (T2). Families will be eligible for the trial if they are identified by implementing organisations as being medium-to-high risk for child protection concerns and have one or more adolescent aged 12–17 who demonstrates significant psychological distress on a self-report brief screening tool. Families will be randomly assigned to a treatment or a waitlist control condition. Families in the waitlist condition will receive a group version of the programme after completion of the study, to allow us to assess feasibility, acceptability, and preliminary indications of intervention effects of this modality. The primary outcome is reduction in overall adolescent-reported psychological distress over time, with post-intervention (T1) as the primary endpoint. Secondary adolescent-reported outcomes include family functioning, psychosocial wellbeing, and emotional regulation difficulties. Secondary caregiver-reported outcomes include parenting style, family functioning, psychological distress, and emotional regulation difficulties. Discussion: This trial will provide the first assessment of the effectiveness of the family systemic psychosocial support intervention for use in Lebanon, with important implications for the use of systemic, low-cost, non-specialist interventions for this age range. Trial registration: Local registry: National Mental Health Program, Ministry of Public Health, Lebanese Republic. Registered on 19 October 2021 Lebanese Clinical Trial Registry LBCTR2021104870

Role of Rac GTPase activating proteins in regulation of NADPH oxidase in human neutrophils

Precise spatiotemporal regulation of O2 --generating NADPH oxidases (Nox) is a vital requirement. In the case of Nox1-3, which depend on the small GTPase Rac, acceleration of GTP hydrolysis by GTPase activating protein (GAP) could represent a feasible temporal control mechanism. Our goal was to investigate the molecular interactions between RacGAPs and phagocytic Nox2 in neutrophilic granulocytes. In structural studies we revealed that simultaneous interaction of Rac with its effector protein p67phox and regulatory protein RacGAP was sterically possible. The effect of RacGAPs was experimentally investigated in a cell-free O2 --generating system consisting of isolated membranes and recombinant p47phox and p67phox proteins. Addition of soluble RacGAPs decreased O 2 - production and there was no difference in the effect of four RacGAPs previously identified in neutrophils. Depletion of membrane-associated RacGAPs had a selective effect: a decrease in ARHGAP1 or ARHGAP25 level increased O2 - production but a depletion of ARHGAP35 had no effect. Only membrane-localized RacGAPs seem to be able to interact with Rac when it is assembled in the Nox2 complex. Thus, in neutrophils multiple RacGAPs are involved in the control of O2 - production by Nox2, allowing selective regulation via different signaling pathways. © 2013 Elsevier Inc

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation &lt;92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p&lt;0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p&lt;0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Rice yellow mottle virus Infection and Reproductive Losses in Rice (Oryza sativa Linn.)

The study on Rice yellow mottle virus (RYMV) infection and reproductive losses in rice was carried out under screenhouse condition in Nigeria. Thirty-five rice varieties were evaluated for RYMV resistance. Percent productive tillers, date to 50% flowering and percent spikelets fertility per plant were between 43.2-96.7%, 57.67-112 days and 0-71.8%, respectively. Number of panicles per plant, number of grains per panicle and 1000 grain weight per plant were between 8.33-45.67, 0-77 and 0-27.57 g, respectively. Yield losses of between 17-100% were obtained from all the rice varieties evaluated. Out of the 35 rice varieties studied, only Gigante (18%), Moroberekan (19%) and NERICA-L 42 (32%), have the least yield losses and RYMV resistance characteristics. The three varieties (Gigante, Moroberekan and NERICA-L 42) are known to possess stable resistance characteristic to RYMV disease and will comparatively be suitable for cultivation in areas where RYMV incidence is endemic and on a long term be used by rice breeders as sources for breeding for durable resistance to RYMV disease in Nigeri

Reactions and Resistance Status of Differential Rice Genotypesto Rice Yellow Mottle Virus, Genus Sobemovirusin Cote d’Ivoire

High yielding rice genotypes with good levels of resistance to RYMV were identified at Africa Rice Center-WARDA in Cote d‘Ivoire. The yields and resistance stability of these genotypes, however, remain uncertain. The performance of 13 genotypes over 10 different RYMV isolates from 7 localities in Cote d’Ivoire was tested in the screenhouse. Chlorophyll (SPAD) and yield reductions due to RYMV disease were evaluated. Considerable diversity was observed in the reactions of these genotypes to all the RYMV isolates. Percentage yields and SPAD reduction were between 2.3-90.3 and 5.3-40%, respectively. Of 13 rice genotypes studied, IR47686-15-1-1(P) had the lowest mean SPAD and yield reductions. The levels of resistance shown by japonicas were better than those of indicas. Six genotypes (FARO 11; GIGANTE (tete); H 232-44-1-1; IR 47686-15-1- 1(P); IR 47686-15-1-1; ITA 235) could be described as possessing both stable and acceptable levels of resistance to RYMV. The high genotype by environment interactions in the reactions of the rice genotypes to RYMV suggests the possible existence of different strains of RYMV in Cote d’Ivoire. This information could be useful in rice breeding programs aiming at deployment of RYMV resistant genotypes to different rice ecologies and localities in Cote d’Ivoire